Aysel Müezzinler1, Ute Mons2, Carolin Gellert3, Ben Schöttker3, Eugène Jansen4, Frank Kee5, Mark G O'Doherty5, Kari Kuulasmaa6, Neal D Freedman7, Christian C Abnet7, Alicja Wolk8, Niclas Håkansson8, Nicola Orsini8, Tom Wilsgaard9, Bas Bueno-de-Mesquita10, Yvonne T van der Schouw11, Petra H M Peeters11, Lisette C P G M de Groot12, Annette Peters13, Philippos Orfanos14, Allan Linneberg15, Charlotta Pisinger16, Abdonas Tamosiunas17, Migle Baceviciene17, Dalia Luksiene17, Gailute Bernotiene17, Pekka Jousilahti6, Ulrika Petterson-Kymmer18, Jan Håkan Jansson19, Stefan Söderberg19, Sture Eriksson20, Nicole Jankovic12, María-José Sánchez21, Giovanni Veronesi22, Susana Sans23, Wojciech Drygas24, Antonia Trichopoulou14, Paolo Boffetta25, Hermann Brenner3. 1. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Network Aging Research, University of Heidelberg, Heidelberg, Germany. 2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: u.mons@dkfz.de. 3. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. National Institute for Public Health and the Environment, Bilthoven, the Netherlands. 5. UKCRC Centre of Excellence for Public Health, Queen's University Belfast, Belfast, Northern Ireland. 6. National Institute for Health and Welfare, Helsinki, Finland. 7. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 8. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 9. Department of Community Medicine, UiT the Arctic University of Norway, Tromsø, Norway. 10. National Institute for Public Health and the Environment, Bilthoven, the Netherlands; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Epidemiology, Julius Center, University Medical Center Utrecht, Utrecht, the Netherlands. 11. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. 12. Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands. 13. Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany. 14. Hellenic Health Foundation, Athens, Greece; Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. 15. Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark; Department of Clinical Experimental Research, Glostrup University Hospital, Glostrup, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 16. Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark. 17. Laboratory of Population Studies, Institute of Cardiology of Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. 18. Department of Public Health and Clinical Medicine, Medicine, Skellefteå Research Unit, Cardiology, Umeå University, Umeå, Sweden; Department of Pharmacology and Clinical Neurosciences, Umeå University, Umeå, Sweden. 19. Department of Public Health and Clinical Medicine, Medicine, Skellefteå Research Unit, Cardiology, Umeå University, Umeå, Sweden. 20. Department of Community Medicine and Rehabilitation, Geriatric Medicine, Umeå University, Umeå, Sweden. 21. Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Granada, Spain; CIBER de Epidemiología y Salud Pública, Barcelona, Spain. 22. Department of Clinical and Experimental Medicine, Research Center in Epidemiology and Preventive Medicine, University of Insubria, Varese, Italy. 23. Institute of Health Studies, Barcelona, Spain. 24. Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, Institute of Cardiology, Warsaw, Poland. 25. Hellenic Health Foundation, Athens, Greece; Tisch Cancer Institute and Institute for Translational Epidemiology, Mount Sinai School of Medicine, New York, New York.
Abstract
INTRODUCTION: Smoking is known to be a major cause of death among middle-aged adults, but evidence on its impact and the benefits of smoking cessation among older adults has remained limited. Therefore, we aimed to estimate the influence of smoking and smoking cessation on all-cause mortality in people aged ≥60 years. METHODS: Relative mortality and mortality rate advancement periods (RAPs) were estimated by Cox proportional hazards models for the population-based prospective cohort studies from Europe and the U.S. (CHANCES [Consortium on Health and Ageing: Network of Cohorts in Europe and the U.S.]), and subsequently pooled by individual participant meta-analysis. Statistical analyses were performed from June 2013 to March 2014. RESULTS: A total of 489,056 participants aged ≥60 years at baseline from 22 population-based cohort studies were included. Overall, 99,298 deaths were recorded. Current smokers had 2-fold and former smokers had 1.3-fold increased mortality compared with never smokers. These increases in mortality translated to RAPs of 6.4 (95% CI=4.8, 7.9) and 2.4 (95% CI=1.5, 3.4) years, respectively. A clear positive dose-response relationship was observed between number of currently smoked cigarettes and mortality. For former smokers, excess mortality and RAPs decreased with time since cessation, with RAPs of 3.9 (95% CI=3.0, 4.7), 2.7 (95% CI=1.8, 3.6), and 0.7 (95% CI=0.2, 1.1) for those who had quit <10, 10 to 19, and ≥20 years ago, respectively. CONCLUSIONS: Smoking remains as a strong risk factor for premature mortality in older individuals and cessation remains beneficial even at advanced ages. Efforts to support smoking abstinence at all ages should be a public health priority.
INTRODUCTION: Smoking is known to be a major cause of death among middle-aged adults, but evidence on its impact and the benefits of smoking cessation among older adults has remained limited. Therefore, we aimed to estimate the influence of smoking and smoking cessation on all-cause mortality in people aged ≥60 years. METHODS: Relative mortality and mortality rate advancement periods (RAPs) were estimated by Cox proportional hazards models for the population-based prospective cohort studies from Europe and the U.S. (CHANCES [Consortium on Health and Ageing: Network of Cohorts in Europe and the U.S.]), and subsequently pooled by individual participant meta-analysis. Statistical analyses were performed from June 2013 to March 2014. RESULTS: A total of 489,056 participants aged ≥60 years at baseline from 22 population-based cohort studies were included. Overall, 99,298 deaths were recorded. Current smokers had 2-fold and former smokers had 1.3-fold increased mortality compared with never smokers. These increases in mortality translated to RAPs of 6.4 (95% CI=4.8, 7.9) and 2.4 (95% CI=1.5, 3.4) years, respectively. A clear positive dose-response relationship was observed between number of currently smoked cigarettes and mortality. For former smokers, excess mortality and RAPs decreased with time since cessation, with RAPs of 3.9 (95% CI=3.0, 4.7), 2.7 (95% CI=1.8, 3.6), and 0.7 (95% CI=0.2, 1.1) for those who had quit <10, 10 to 19, and ≥20 years ago, respectively. CONCLUSIONS: Smoking remains as a strong risk factor for premature mortality in older individuals and cessation remains beneficial even at advanced ages. Efforts to support smoking abstinence at all ages should be a public health priority.
Authors: Naoko Sasamoto; Tianyi Wang; Mary K Townsend; A Heather Eliassen; Fred K Tabung; Edward L Giovannucci; Ursula A Matulonis; Kathryn L Terry; Shelley S Tworoger; Holly R Harris Journal: Br J Cancer Date: 2022-06-27 Impact factor: 9.075
Authors: Charles J Holahan; Penny L Brennan; Kathleen K Schutte; Carole K Holahan; J Gregory Hixon; Rudolf H Moos Journal: Alcohol Clin Exp Res Date: 2018-02-27 Impact factor: 3.455
Authors: José Manuel Ordóñez-Mena; Ben Schöttker; Ute Mons; Mazda Jenab; Heinz Freisling; Bas Bueno-de-Mesquita; Mark G O'Doherty; Angela Scott; Frank Kee; Bruno H Stricker; Albert Hofman; Catherine E de Keyser; Rikje Ruiter; Stefan Söderberg; Pekka Jousilahti; Kari Kuulasmaa; Neal D Freedman; Tom Wilsgaard; Lisette Cpgm de Groot; Ellen Kampman; Niclas Håkansson; Nicola Orsini; Alicja Wolk; Lena Maria Nilsson; Anne Tjønneland; Andrzej Pająk; Sofia Malyutina; Růžena Kubínová; Abdonas Tamosiunas; Martin Bobak; Michail Katsoulis; Philippos Orfanos; Paolo Boffetta; Antonia Trichopoulou; Hermann Brenner Journal: BMC Med Date: 2016-04-05 Impact factor: 8.775